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Abstract: Antimicrobial resistance (AMR) remains an important global public health issue with
antimicrobial misuse and overuse being one of the main drivers. The Global Point Prevalence Survey
(G-PPS) of Antimicrobial Consumption and Resistance assesses the prevalence and the quality of
antimicrobial prescriptions across hospitals globally. G-PPS was carried out at 17 hospitals across
Ghana, Uganda, Zambia and Tanzania. The overall prevalence of antimicrobial use was 50% (30–57%),
with most antibiotics prescribed belonging to the WHO ‘Access’ and ‘Watch’ categories. No ‘Reserve’
category of antibiotics was prescribed across the study sites while antimicrobials belonging to the
‘Not Recommended’ group were prescribed infrequently. Antimicrobials were most often prescribed
for prophylaxis for obstetric or gynaecological surgery, making up between 12 and 18% of total
prescriptions across all countries. The most prescribed therapeutic subgroup of antimicrobials was
‘Antibacterials for systemic use’. As a result of the programme, PPS data are now readily available
for the first time in the hospitals, strengthening the global commitment to improved antimicrobial
surveillance. Antimicrobial stewardship interventions developed included the formation of AMS
committees, the provision of training and the preparation of new AMS guidelines. Other common
interventions included the presentation of findings to clinicians for increased awareness, and the
promotion of a multi-disciplinary approach to successful AMS programmes. Repeat PPS would be
necessary to continually monitor the impact of interventions implemented. Broader participation is
also encouraged to strengthen the evidence base.
Keywords: antimicrobial resistance; global-pps; antimicrobial surveillance; antibiotics; antimicro-
bials; antimicrobial stewardship
1. Introduction
Antimicrobial resistance (AMR) is a global, public, and individual health challenge
affecting the delivery of safe, effective healthcare in all settings and all countries. The
ability of microorganisms to become resistant to the effect of antimicrobials is an inevitable
evolutionary process; however, misuse and over-use of antimicrobial agents hastens the
development and spread [1,2].
AMR leads to increased mortality rates [3] and duration and cost of patient care [1].
This is of particular concern in low- and middle-income countries (LMICs) due to the
reduced availability of appropriate equipment and/or appropriate diagnostic tools, as well
as challenges with access to quality antimicrobials [4–7]. The rise in incidence of AMR
has led to an increased global focus on antimicrobial stewardship (AMS). Surveillance of
antimicrobial use and resistance are core to all AMS activities and understanding how
antimicrobials are used allows for a review of current practices and highlights areas for
improvement. Point prevalence surveys (PPSs) are a widely recognised surveillance
method requiring limited resources to collect information on antimicrobial prescribing
practices and other relevant factors in hospitalized patients [8–11].
PPS are a key resource when planning and supporting national and local steward-
ship interventions in a range of settings, offering a standardised method for comparing
data on antimicrobial use across hospitals and countries. The Global Point Prevalence
Survey of Antimicrobial Consumption and Resistance (G-PPS; www.global-pps.com/,
accessed on 15 May 2021) aims to assess the global prevalence of antimicrobial prescribing
and resistance, with an emphasis on countries with low resources, support, and exper-
tise and supports antimicrobial stewardship programs in order to enhance appropriate
antimicrobial prescribing [12].
Alongside the evaluation of antimicrobial prescribing practices in hospitals, PPS
can identify targets for quality improvement of antimicrobial prescribing and implement
and monitor the impact of interventions through repeated surveys. One of the main
aims in strengthening global AMS is to reduce the use of antimicrobials that are in the
World Health Organization’s (WHO) ‘Watch’ and ‘Reserve categories’ and ‘Not Recom-
mended’ group of their AWaRe framework [13,14]. The framework recommends preferred
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antimicrobial choice for treating common infections—the ‘Access’ category, based on con-
sideration of benefits versus risks to patients and the potential for resistance. An additional
classification—‘Not recommended’ was added to the framework more recently to include
fixed-dose combinations of broad-spectrum antibiotics for which use is not evidence-
based [15]. Similarly, the Anatomic Therapeutic Chemical (ATC) classification categorizes
drugs active substances into different groups and subgroups according to their therapeutic,
pharmacological and chemical properties. WHO endorses the ATC classification as the
standard for drug utilization monitoring and research [16].
The Commonwealth Partnerships for Antimicrobial Stewardship programme (Cw-
PAMS), managed by the Commonwealth Pharmacists Association (CPA) and Tropical
Health and Education Trust (THET), is a health partnerships programme funded by the
UK Official Development Assistance (ODA), through the Department of Health and Social
Care’s Fleming Fund to address AMR globally [17]. The aim of the programme is to
enhance the implementation of protocols and evidenced-based decision making to support
antimicrobial prescribing and the capacity for surveillance of antimicrobial consumption
and stewardship.
The CwPAMS programme included 12 partnerships between UK health institutions
and counterparts in four African Commonwealth countries: Ghana (GH), Uganda (UG),
Zambia (ZM), and Tanzania (TZ). The partnerships consisted of volunteer health workers
and experts from the five countries who shared skills and knowledge to co-develop strate-
gies to address AMR and AMS. As part of the fulfillment of the aims of the partnership, a
Global Point Prevalence Study was used to obtain baseline data and measure the impact of
the implementation of AMS programmes across partnership countries.
This paper aims to compare national data on antimicrobial use obtained from 12
hospitals across four countries (Ghana (6), Uganda (4), Zambia (1) and Tanzania (1)) and
identify target points for improvement. As part of an additional collaboration, PPS data
from a further four hospitals in Ghana and one additional hospital in Zambia (which
collected data using the Global PPS platform during the same period as the CwPAMS
programme), are also included in the study.
2. Results
2.1. Characteristics of Included Hospitals and Eligible Patients
A total of 4376 patients were included in the survey, with 2169 (50%) treated with
antimicrobials across the four countries. From the total number of treated patients, 1366
(63%) were from 10 hospitals in Ghana, 386 (17.8%) from four hospitals in Uganda, 238
(11%) from two hospitals in Zambia, and 179 (8%) from one hospital in Tanzania (Table 1).
Of the 17 hospitals included, 3 were identified as primary care, 6 as secondary care and 8
as tertiary care. Additionally, eight hospitals were classed as teaching hospitals, three in
both Uganda and Ghana and one in both Zambia and Tanzania.
Table 1 summarises the general characteristics of the patients surveyed across the four
countries. More adults were included across all sites than children or neonates. A greater
proportion of children were included in Uganda (35%) than the other three countries
(Ghana (19%), Tanzania (16%), Zambia (15%). Activities of the wards where patients were
surveyed were relatively uniform across the countries, with patients on intensive care
wards (IC) making up the smallest proportion of those surveyed (4–20%).
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Table 1. Characteristics of wards and patients (treated with at least one antimicrobial) in PPS conducted at 17 hospitals.
Characteristics Ghana Uganda Zambia Tanzania
Number of Hospitals 10 4 2 1
Number of Treated Patients 1366 386 238 179
Patient Age
Neonate (≤1 month) 150 (11%) 20 (5%) 32 (13%) 34 (19%)
Child (>1 month–≤17 years) 261 (19%) 136 (35%) 35 (15%) 29 (16%)
Adult (≥18 years) 955 (70%) 214 (56%) 171 (72%) 116 (65%)
Unknown - 16 (4%) - -
Patient Gender
Male 570 (41.7%) 162 (42%) 96 (40%) 93 (52%)
Female 794 (58.1%) 205 (53%) 142 (60%) 84 (46.9%)
Unknown 2 (0.2%) 19 (5%) - 2 (1.1%)
Ward Activity
Medicine 76 (46%) 28 (54%) 9 (45%) 7 (35%)
Surgery 74 (45%) 22 (42%) 7 (35%) 10 (50%)
Intensive Care 15 (9%) 2 (4%) 4 (20%) 3 (15%)
2.2. Prevalence of Antimicrobial Use
The prevalence of antimicrobial use (AMU) was 50% from the 17 sites across the four
countries (Table 2). The proportion of patients treated with antimicrobials at the time of the
survey was highest in Zambia (57%), followed by Ghana (55%) and Uganda (45%), and
was lowest in Tanzania (30%).
Table 2. Prevalence of antimicrobial use in four countries included in PPS.
Country Admitted Patients Treated Patients Prevalence of AMU (%)
Ghana 2502 1366 55
Uganda 862 386 45
Zambia 418 238 57
Tanzania 594 179 30
Total 4376 2169 50
There was a total of 3838 prescriptions recorded in the survey, 2435 (63%) of which
were reported from hospitals in Ghana, 710 (18.5%) from Uganda, 402 (10.5%) from Zambia,
and 290 (7.5%) from Tanzania.
Of these prescriptions, those in the ATC J01 category (antibacterials for systemic use)
were further classified into each of the WHO AWaRe categories (Figure 1). There was no
reported use (0%) of the Reserve category of antibiotics in any of the four countries.
Antibiotics 2021, 10, x FOR PEER REVIEW 5 of 16 
 
143, Tanzania 38%; n = 109). There was no reported use (0%) of the Reserve category anti-
biotics in any of the four countries. 
 
Figure 1. The proportion of antibiotics in the ACT J01 group prescribed in each of four countries. 
‘Not Recommended’ antibiotic combinations were prescribed in Uganda, Tanzania, 
and Ghana. Ugandan hospitals had the highest prescription rate of these drugs (8%; 
48/592) with 47 prescriptions of Ampiclox®® (ampicillin and cloxacillin) (7% of total pre-
scriptions) and one of ciprofloxacin and metronidazole. In Tanzania, Ampiclox®® was pre-
scribed on 9 occasions (3% of total prescriptions). In Ghana, the “Not Recommended” 
group of antibiotics made up 0.2% of antibiotic prescriptions (4/1212) with ceftriax-
one/beta-lactamase inhibitor being prescribed twice, ceftriaxone in combination with an-
other unspecified antibiotic prescribed once and penicillin in combination with another, 
unspecified antibacterial also prescribed once. Unclassified antibiotics were prescribed 
very infrequently in all countries. 
The proportion of antimicrobials used, as grouped according to the ATC classifica-
tion level 1, is shown in Table 3. For all countries, antibacterials for systemic use (J01) were 
the most frequently prescribed, making up 83–99% of prescriptions. Additionally, in 
Ghana, Uganda, and Zambia, antiprotozoals used as antibacterials (P01AB) made up 4–
10% of the prescriptions. Uganda had the highest proportion of prescriptions for antima-
larials (P01B) at 4.6% of the total and drugs for treatment of tuberculosis (J04A) at 4.5% of 
the total. Rates for antibiotics used as intestinal anti-infectives (A07AA), antimycotics and 
antifungals for systemic use (J02; D01BA) and antivirals for systemic use (J05) were low 
(0–2%) for all four countries. 
Table 3. Proportional antimicrobial use by country grouped by therapeutic subgroup. 
Therapeutic Subgroup 
Proportional Antimicrobial Use (% of Prescriptions) 
Ghana Uganda Zambia Tanzania 
Antibacterials for systemic use (J01) 85.1 83.4 86.3 99.3 
Antimycotics and antifungals for systemic use (J02; D01BA) 0.8 1.3 2.2 0.3 
Drugs for treatment of tuberculosis (J04A) 1.2 4.5 0.2 0 
Antibiotics used as intestinal anti-infectives (A07AA) 0.5 0.3 0.2 0 
Antiprotozoals used as antibacterial agents (P01AB) 8.3 4.2 10.2 0.3 
Antivirals for systemic use (J05) 1.4 1.7 0 0 
Antimalarials (P01B) 2.8 4.6 0.7 0 
The most prescribed antimicrobial across Ghanaian hospitals was metronidazole for 
systemic use (12% of total prescriptions; 288/2435), compared to ceftriaxone which was 
prescribed most frequently in the three other countries; Uganda 24% (173/710), Zambia 
21% (83/402), and Tanzania 32% (94/290). Full details of the proportions of antimicrobials 
prescribed in each country can be found in the supplementary data (Tables S1 and S2). 
  
Figure 1. The proportion of antibiotics in the ACT J01 group prescribed in each of four countries.
Antibiotics 2021, 10, 1122 5 of 15
Antibiotics in the WHO access category were prescribed more frequently than those
in other categories across all countries and were prescribed at similar rates, accounting for
60% of the total of ATC J01 antibiotics prescribed in Ghana (1212/2071), 52% in Uganda
(309/592), 58% in Zambia (201/347), and 59% in Tanzania (170/288) (Figure 1). Antibiotics
in the Watch category were the second most frequently prescribed, again with proportions
being similar for all countries (Ghana 42%; n = 851, Uganda 39%; n = 232, Zambia 41%
n = 143, Tanzania 38%; n = 109). There was no reported use (0%) of the Reserve category
antibiotics in any of the four countries.
‘Not Recommended’ antibiotic combinations were prescribed in Uganda, Tanzania,
and Ghana. Ugandan hospitals had the highest prescription rate of these drugs (8%; 48/592)
with 47 prescriptions of Ampiclox®® (ampicillin and cloxacillin) (7% of total prescriptions)
and one of ciprofloxacin and metronidazole. In Tanzania, Ampiclox®® was prescribed on 9
occasions (3% of total prescriptions). In Ghana, the “Not Recommended” group of antibi-
otics made up 0.2% of antibiotic prescriptions (4/1212) with ceftriaxone/beta-lactamase
inhibitor being prescribed twice, ceftriaxone in combination with another unspecified
antibiotic prescribed once and penicillin in combination with another, unspecified antibac-
terial also prescribed once. Unclassified antibiotics were prescribed very infrequently in
all countries.
The proportion of antimicrobials used, as grouped according to the ATC classification
level 1, is shown in Table 3. For all countries, antibacterials for systemic use (J01) were the
most frequently prescribed, making up 83–99% of prescriptions. Additionally, in Ghana,
Uganda, and Zambia, antiprotozoals used as antibacterials (P01AB) made up 4–10% of the
prescriptions. Uganda had the highest proportion of prescriptions for antimalarials (P01B)
at 4.6% of the total and drugs for treatment of tuberculosis (J04A) at 4.5% of the total. Rates
for antibiotics used as intestinal anti-infectives (A07AA), antimycotics and antifungals for
systemic use (J02; D01BA) and antivirals for systemic use (J05) were low (0–2%) for all
four countries.
Table 3. Proportional antimicrobial use by country grouped by therapeutic subgroup.
Therapeutic Subgroup Proportional Antimicrobial Use (% of Prescriptions)
Ghana Uganda Zambia Tanzania
Antibacterials for systemic use (J01) 85.1 83.4 86.3 99.3
Antimycotics and antifungals for systemic use (J02; D01BA) 0.8 1.3 2.2 0.3
Drugs for treatment of tuberculosis (J04A) 1.2 4.5 0.2 0
Antibiotics used as intestinal anti-infectives (A07AA) 0.5 0.3 0.2 0
Antiprotozoals used as antibacterial agents (P01AB) 8.3 4.2 10.2 0.3
Antivirals for systemic use (J05) 1.4 1.7 0 0
Antimalarials (P01B) 2.8 4.6 0.7 0
The most prescribed antimicrobial across Ghanaian hospitals was metronidazole for
systemic use (12% of total prescriptions; 288/2435), compared to ceftriaxone which was
prescribed most frequently in the three other countries; Uganda 24% (173/710), Zambia
21% (83/402), and Tanzania 32% (94/290). Full details of the proportions of antimicrobials
prescribed in each country can be found in the supplementary data (Tables S1 and S2).
2.3. Reason for Prescribing Antimicrobials
The main reasons for prescribing antimicrobials for each country are shown in Figure 2.
Across all countries, antimicrobials were most often prescribed for prophylaxis for obstetric
or gynaecological surgery, making up between 12 and 18% of total prescriptions (Figure 2).
Antimicrobials were next most frequently prescribed for pneumonia or lower respiratory
tract infections, in all but Tanzania, where drugs used as medical prophylaxis for new-born
risk factors was the second most common reason for prescribing (15% of total).
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Figure 2. Most common reason for prescribing antimicrobials across 17 hospitals participating in the PPS.
In Ghana, the third most common reason for prescribing was to treat skin and soft
tissue infections (equal to prescriptions for completely unknown infections). Uganda had
a higher prescription rate for prophylaxis for plastic or orthopaedic surgery than other
countries (8%) and prescriptions for infections of the central nervous system were higher
in Zambia (8%). Drugs were frequently prescribed for sepsis across all countries (7–9%).
Across all four countries, antimicrobials were frequently prescribed for prophylaxis.
This practice was highest in Tanzania, with 48% of all prescribed antimicrobials being for
prophylaxis. This was followed by in Ghana (33%), Uganda (27%) and Zambia (27%).
Proph OBGY—prophylaxis for obstetric or gynaecological surgery (caesarean section,
no episiotomy, carriage of group B streptococcus); pneu—pneumonia or lower respiratory
tract infections; UNK—prescriptions for completely unknown infections; SST—skin and
soft tissue infections (cellulitis, wound including surgical site infection, deep soft tissue not
involving bone, e.g., infected pressure or diabetic ulcer, abscess); proph BJ—prophylaxis
for plastic or orthopaedic surgery (bone or joint); CNS—prescriptions for infections of the
central nervous system; NEO-MP—medical prophylaxis for new-born risk factors, e.g.,
VLBW (very low birth weight) and IUGR (intrauterine growth restriction).
Out of 4376 admitted inpatients, 237 patients (5.4%; range 4.1% in Uganda to 5.1% in
Zambia) were treated with antibiotics for systemic use (ATC J01) for at least one healthcare
associated infection. Table 4 shows the types of indication for which antimicrobials were
prescribed by country. Out of all therapeutic prescribing, community-acquired infections
were the most common indication for antimicrobial use. Surgical prophylaxis of >1 day
(SP3) was common in all countries, up to 97% of all prescriptions for surgical prophylaxis
in Tanzania and Uganda (Table 4). Ghana recorded most antimicrobial prescriptions for
which the indication was not known (11%).
Table 4. Type of indication for antimicrobial prescribing.
Ghana Tanzania Uganda Zambia
Total Number of Prescriptions 2435 290 710 402
Therapeutic use 1344 (55.2%) 134 (46.2%) 477 (67.2%) 288 (71.6%)
Community-Acquired infection; CAI 1074 (79.9%) 89 (66.4%) 416 (87.2%) 257 (89.2%)
Healthcare-Associated Infection; HAI 270 (20.1%) 45 (33.6%) 61 (12.8%) 31 (10.8%)
Prophylactic use 805 (33.1%) 145 (50.7%) 225 (31.7%) 102 (25.4%)
Medical Prophylaxis; MP 172 (7%) 46 (16%) 50 (7%) 17 (4%)
Surgical Prophylaxis; SP 633 (26.0%) 99 (34.1%) 175 (24.6%) 85 (21.1%)
Surgical Prophylaxis One dose; SP1 42 (6.6%) 3 (3.0%) 2 (1.1%) 1 (1.1%)
Surgical Prophylaxis One day; SP2 113 (17.9%) 0 (0%) 3 (1.7%) 2 (2.3%)
Surgical Prophylaxis > 1 day; SP3 478 (75.5%) 96 (97.0%) 170 (97.1%) 83 (96.5%)
Other (OTH) 19 (0.7%) 1 (0.3%) 1 (0.1%) 8 (2%)
Unknown (UNK) 267 (11%) 10 (3%) 7 (1%) 4 (1%)
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As mentioned above, one common indication for prescribing antimicrobials in all
countries was for prophylaxis for obstetric or gynaecological surgery. The types of antimi-
crobials prescribed for this indication differed across the four countries. In participating
hospitals in Ghana, 16 different drugs were prescribed for OBGY prophylaxis (Table 5), with
metronidazole comprising 44% of prescriptions for this indication (186/425). This was split
relatively evenly between oral (95/186; 22% of total number of prescriptions) and parenteral
administration (91/186; 21.4% of total prescriptions). Of the 186 times metronidazole was
prescribed, it was co-administered with another antimicrobial (88%; 164/186). When given
orally, it was most commonly prescribed with co-amoxiclav; amoxicillin/clavulanic acid
(42/95) and, when given parenterally, it was most commonly prescribed with co-amoxiclav
(23/91) or ceftriaxone (22/91).
Table 5. Antimicrobials prescribed for prophylactic OBGY purposes in Ghana (% of total) and AWaRe
group.
ATC Code Drug % of Prescriptionsfor Proph-OBGY
AWaRe
Classification
P01AB01 Oral Metronidazole 22.4 Access
J01XD01 Parenteral Metronidazole 21.4 Access
J01CF02 Co-amoxiclav/Amoxicillinand enzyme inhibitor 21.6 Access
J01DC02 Cefuroxime 11.8 Watch
J01CA04 Amoxicillin 9.9 Access
J01DD04 Ceftriaxone 6.4 Watch
J01MA02 Ciprofloxacin 1.6 Watch
J01GB03 Gentamicin 1.4 Access
J01FF01 Clindamycin 1 Access
J01FA10 Azithromycin 0.5 Watch
J01AA02 Doxycycline 0.5 Access
J01MA12 Levofloxacin 0.5 Watch
P01AB07 Secnidazole 0.5 Unclassified
J01DD13 Cefpodoxime 0.2 Watch
J01CF05 Flucloxacillin 0.2 Access
J02AC01 Fluconazole 0.2 Unclassified
Again, in Ghana, co-amoxiclav was prescribed as a single agent on 19% of occasions
(81/425) and, as described, frequently co-administered with metronidazole (65/186). Ce-
furoxime was the next most frequently prescribed on 12% of occasions (50/425). The top
two drugs that were most prescribed in the participating hospitals in Ghana were in the
access category, whereas ceftriaxone is in the Watch category. Whilst the most common
reason for prescribing antimicrobials was the same for the other 3 countries, there was less
variation in drug type (Figure 3).
In Uganda, metronidazole and ceftriaxone were prescribed together frequently for
proph OBGY. Metronidazole was prescribed 47.1% of total prescriptions for proph OBGY
(41/87) and ceftriaxone 44% (38/87) (Figure 3). They were co-prescribed on 37 occasions,
with ceftriaxone only being prescribed alone once for this indication. All but two prescrip-
tions for metronidazole were parenteral administration.
Metronidazole and ceftriaxone were both prescribed for proph OBGY with the same
frequency in Tanzania (49%) but were not co-administered on any occasion to the same
patient. Metronidazole was also the most prescribed antimicrobial for prophylactic OBGY
purposes in Zambia (44%) and was frequently co-administered with amoxicillin (22%)
(Figure 3).
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2.5. Quality Indicators for Prescribing
Quality indicators for all prescriptions were recorded during each survey and include
criteria from the GPPS protocol [18] as shown in Table 6. Stop/review dates (i.e., whether
a date of review or stop date of the antimicrobial was recorded in the medical records)
were almost always reported in both Uganda (99% of prescriptions) and Tanzania (99%).
Indications for prescriptions were well-documented ranging from 66% of all prescriptions
in Ghana to 97% in Uganda. The proportion of prescriptions that were guideline-compliant
varied widely among the four countries from 55% in Zambia, to 88% in Tanzania (Table 6).
Ghana most frequently reported the absence of antimicrobial prescription guidelines (13%).
Moreover, in Ghana, in 1096 antimicrobial prescriptions (45%), the information with respect
to the guidelines was not assessable because the indication was unknown.
Table 6. Proportion of total prescriptions of all antimicrobials for each of the 4 quality indicators (% of total).
Quality Indicator Ghana Uganda Zambia Tanzania
Total number of prescriptions 2435 710 402 290
Prescriptions with a documented stop/review date 1579 (67%) 700 (99%) 82 (20%) 289 (99%)
Prescriptions with a documented indication 1601 (66%) 687 (97%) 321 (80%) 248 (86%)
Prescriptions that were guideline-compliant * 858 (84%) 413 (67%) 195 (55%) 237 (88%)
Prescriptions for which no guidelines were available (NA) 313 (13%) 36 (5%) 38 (10%) 1 (0.3%)
* Guideline compliance is calculated as compliance to guidelines (Yes) when guidelines are existing (Yes + No).
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2.6. Antimicrobial Stewardship Interventions as a Result of PPS
The key antimicrobial stewardship interventions that were implemented as a result
of the PPS data in the CwPAMS programme institutions are summarised in Table 7 with
further details in SInfo1: Antimicrobial Stewardship Intervention summaries.
Table 7. AMS interventions at 16 of the 17 hospitals in response to the PPS carried out.
Hospital
AMS Intervention 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
New guidelines developed X X X X X X X X X X
Catalyst for forming AMS
committee X X X X X X X X X X X X
Improved access to guidelines
through:
Posters X X X
Printed copies X X X X
Promotion of CwPAMS app X X X X X X
Other: Please state X
Training sessions X X X X X X X X X X X X X X X
Repeat PPS conducted and
submitted G-PPS platform X X X X
Repeat PPS conducted and
analysed internally X X X X X X X X
AMS awareness raising X X X X X X X X X
Data presented to clinicians X X X X X X X X X X X
Data presented to AMS committee
or DTC X X X X X X X X
Activities for WAAW X X X X X X
Antibiogram developed X
Drug chart updated or created X X X
Improved laboratory services X X X X X X X
Other: Please list below









No details provided by hospital 17.
3. Discussion
The Point Prevalence Surveys presented provide key insights into antibiotic prescrib-
ing in selected public or not-for-profit hospitals across Ghana, Tanzania, Uganda, and
Zambia. The overall prevalence of antimicrobial use was 50% (30–57%), with most antibi-
otics prescribed belonging to the WHO ‘Access’ and ‘Watch’ groups. No ‘Reserve’ category
antibiotics were prescribed across the study sites; however, there were some prescriptions
of ‘Not Recommended’ antibiotic combinations. While this pattern of antibiotic use may
partly be due to the prescriber’s consideration of optimality and potential for antimicrobial
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resistance, in line with WHO’s goal of improving antibiotic use through antimicrobial
stewardship [19], other authors suggest alternative reasoning [20,21].
Antibiotic prescribing patterns were significantly associated with accessibility and
affordability, with broad-spectrum antibiotics in the Access category being more readily
available and affordable than antibiotics in the Watch and Reserve categories and the
‘Not Recommended’ group [20,21]. A recent study on antibiotic availability and use in 20
low- and middle-income countries reported that the median proportion of facilities across
countries with availability of Access category antibiotics was 89.5% [22]. Pauwels et al.
(2021) reported that low-income countries had the highest percentage of use of Access cate-
gory antibiotics (63%), the lowest use of Watch category antibiotics (36%) and no Reserve
category prescriptions on adult wards across 69 countries [23]. A PPS conducted across
six referral hospitals in Tanzania also supports data presented in the current study, report-
ing 62% of prescriptions for in-patients being from the Access group [24]. In addition to
availability and affordability, the similarity in prescription patterns across all four countries
in the current study might be associated with the circulating bacterial strains and disease
burden across low- and middle-income countries [6,7,25]. The WHO proposes that the
AWaRe classification should support monitoring of antibiotic prescribing and inform AMS
programmes and has the target that by 2023 at least 60% of national antibiotic consumption
should come from the Access category [15]. In data presented here, 60% of the total of ATC
J01 antibiotics prescribed in Ghana (1212/2071), 52% in Uganda (309/592), 58% in Zambia
(201/347) and 59% in Tanzania (170/288) were in the Access category, demonstrating the
hospitals’ alignment with the WHO target for national antibiotic consumption.
The antibiotics most commonly prescribed across hospitals in all four countries in
the current study were metronidazole and ceftriaxone, with metronidazole being the most
prescribed antibiotic across Ghanaian hospitals. These findings are supported by data from
the Pauwels et al. study across 69 countries, where ceftriaxone was the most commonly
used antibiotic for therapeutic use on adult wards worldwide. In the same study, up to 24%
of prescriptions for surgical prophylaxis in sub-Saharan Africa were for metronidazole,
followed by ceftriaxone (23%) [23]. A PPS carried at the Korle-Bu Teaching Hospital
in Ghana (2018) reported metronidazole as the most frequently prescribed antibiotic,
followed by amoxicillin-clavulanic acid, cephalosporins (ceftriaxone, cefuroxime), and
cloxacillin [26]. A PPS in Kenya also recorded a higher use of nitroimidazoles compared to
beta-lactam antibiotics [27]. Furthermore, a PPS in three hospitals in north-eastern Tanzania
reported ceftriaxone, metronidazole, and penicillin as the most prescribed antibiotics [28].
Metronidazole is effective in the treatment of a broad range of anaerobic infections
which may be more common in African countries [29]. Metronidazole was used in addi-
tion to co-amoxiclav, so this could perhaps be an area to target to reduce use if anaerobic
infections are covered by use of other antibiotics. This highlights that it might be useful to
increase the awareness and understanding of antibiotic sensitivity. The findings presented
here show that metronidazole was primarily prescribed for prophylaxis for obstetrics
and gynaecology. Published data demonstrate a similarity between the most commonly
prescribed antibiotics in PPSs carried out in other low-income countries. This could be
explained by the affordability, availability, and the spectrum of activity of metronidazole
and ceftriaxone, as well as their suitability for prophylaxis in certain obstetric and gy-
naecological procedures [30]. However, the broad-spectrum activity of some antibiotics,
particularly cephalosporins, can lead to the over-growth of other bacteria that are resistant
to their activity, for example Clostridiodies difficile, methicillin-resistant Staphylococcus aureus
(MRSA), and vancomycin-resistant enterococci (VRE) [31,32]. The use of cephalosporins, in
particular, and third-generation drugs such as ceftriaxone, are linked to the rise in incidence
of extended-spectrum beta-lactamase (ESBLs)-producing bacteria, leading to a reduction
of effective antibiotics [33,34]. Therefore, there remains a need to evaluate prescriber’s
choices and the frequent prescription of ceftriaxone, which falls within the Watch group of
antibiotics in the WHO AWaRe categories.
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Reasons for antimicrobial prescribing in other published studies demonstrate a similar
pattern to the current study, with lower respiratory tract infections and medical and surgical
prophylaxis presented as common reasons for prescribing [24,25]. Prophylaxis for obstetric
or gynaecological surgery was the most frequent reason for prescribing in the current study.
Although the reasons for antimicrobial prescribing were similar across all four countries,
Uganda had the highest prescription rates for antimalarials, drugs for the treatment of
tuberculosis (TB). The WHO Global Tuberculosis Report (2020) reported Zambia having the
highest incidence of TB (of the four countries included here) in 2019 (300–499 incidences
per 100,000 population per year), followed by Tanzania (200–299 incidences per 100,000
population per year) and Ghana and Uganda having similar, lower rates (10–99 incidences
per 100,000 population per year) [35]. It is possible that there were localised TB and malaria
outbreaks in the regions where the Ugandan hospitals were, but data are not available
to confirm or deny this. This data may also be influenced by the time of year the PPS
was carried out. If the PPS was conducted in the rainy season, then prescriptions for
antimalarials might be higher than if the PPS was done in the dry seasons. The reason
for this could also be that TB detection methods may be more robust in Uganda, which
may explain the lower prevalence of disease but higher use of drugs. Further analysis and
PPS would be required to explain the higher observed rates for unclassified antimicrobials
and drugs used in the treatment of TB and malaria seen in Uganda. Antimicrobials were
often prescribed when indication was documented (Figure 2). There is a need to improve
diagnostic capacity as diagnostic uncertainty might lead to the increase of antimicrobial
prescribing [36].
From the 4376 admitted inpatients across the 4 countries, 5.4% were treated with
antibiotics for systemic use for at least one healthcare-associated infection (HCAI). Out of
all therapeutic prescribing, community acquired infections were the most common reason
for antimicrobial use. The rates of HCAI were similar to a large study conducted across
acute care facilities in 28 countries in the EU/EAA, where 6.5% of patients had at least one
HCAI [37]. Although the European study was conducted over a much larger sample group,
the data show a trend towards similar rates of HCAI in the data presented in this study.
The chi-squared test of association revealed significant associations between age,
gender, countries, and AWaRe categories. Although the exact nature of the relation-
ship between variables is uncertain, the summary statistics (Supplementary Material:
Tables S3–S5) provide more insight into these associations. As observed from descriptive
analysis, reasons for antibiotic prescribing differ across populations with some age-specific
indications such as ‘medical prophylaxis for new-born risk factors’ mostly observed in
Tanzania and Uganda and gender-specific indications such as ‘prophylaxis for obstetric
or gynaecological surgery’ observed across all countries. While these partly explain sig-
nificant associations between antibiotic prescribing, gender, and age in specific countries
and the general population, our results reflect country-specific trends worthy of further
investigation.
Through the Global PPS programme and CwPAMS (for the participating hospitals),
all partnerships and additional hospitals in Ghana and Zambia have demonstrated the
strengthening of their healthcare workforce knowledge and capacity (Table 7) in the areas of
antimicrobial use surveillance and AMS. Prior to the programme, although other hospitals
had collated antimicrobial use data through PPS methodology, only one hospital in the
four countries had previously conducted data collection to the scale of the Global PPS.
Translating PPS findings into contextualised interventions can be challenging but all
CwPAMS health partnerships and hospitals involved have provided information regarding
key AMS interventions taken as a result of the Global PPS undertaken at their institutions.
These are summarised in Table 7 (for the full text, see Supplementary Data). In an evaluation
of the impact of the Global-PPS on local AMS programmes, prolonged surgical antibiotic
prophylaxis was the most common target for improvement identified [38]. This study also
highlights the need to focus on prolonged surgical antibiotic prophylaxis considering that
prescriptions for more than one day for surgical prophylaxis were common. However,
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antibiotics are only one component that can be used to reduce SSI. The inability to ensure a
sterile environment and optimal IPC conditions may result in overuse or antibiotics.
Variations in quality indicators were observed across countries. Consistent with this
study, the PPS in 6 reference hospitals in Tanzania observed an 84% adherence of antibiotic
prescriptions to the National Standard Treatment Guideline [24]. Similarly, a multi-centre
PPS in Ghana also recorded a level of non-compliance to national antimicrobial standard
treatment guidelines [39]. The variations observed could be influenced by varying national
antimicrobial prescribing policies, hospital protocols and the effectiveness of antimicrobial
stewardship intervention programs in study centres across all four countries.
The consistency of data collection via the G-PPS methodology adds rigor and validity
to the data presented here. The study demonstrates inclusivity with data obtained from 17
hospitals across four countries in 3 African regions, coupled with a good representation
of gender, age groups, and hospital sections. In addition, data were collected by trained
health professionals working, for the most part, as part of the Commonwealth Partnerships
for Antimicrobial Stewardship.
4. Materials and Methods
Training on the collection of surveillance data for the G-PPS reported in this paper
was provided to the CwPAMS health partnerships by the Global PPS team and the CPA,
supporting the development of evidence-based standards, guidelines, protocols and the
development of a mentorship programme to support sustainability. UK volunteers who
had experience of PPS also provided mentorship and in-country support during their visits
to Ghana, Uganda, Zambia, and Tanzania. Data collection was carried out by volunteers
from individual health partnerships. PPS were conducted between May and December
2019, using the G-PPS methodology as described elsewhere [18]. Data from 17 hospitals
across four countries: ten in Ghana, four in Uganda, two in Zambia and one in Tanzania
were collected and analysed. Follow-up data were collected in a second PPS for two
hospitals but only the data from the first survey are included here.
Age of patients were defined as: adult (≥18 years) Child (>1 month–≤17 years) or
neonate (≤1 month). Gender, age, diagnosis (reason for prescribing), indication (therapeu-
tic versus prophylactic prescribing), routes of administration, prescribed antimicrobials
dosing regimen, and causative microorganisms were all recorded. Data collection also
included a set of prescription-related quality indicators; Prescriptions with a documented
stop/review date, prescriptions with a documented indication, prescriptions that were
guideline compliant and prescriptions for which no guidelines were available. The G-PPS
data collection form is available via: https://www.global-pps.com/documents/ (accessed
on 15 September 2021).
Hospitals were classified as primary, secondary, or tertiary care hospitals. All inpa-
tients admitted at 8 a.m. on the day of the PPS were included and data were analysed by
country and ward type. The included wards were neonatal medical and intensive-care
units, paediatric medical, surgical or haematology-oncology ward and intensive-care units
and adult medical, pneumology, surgical, haematology-oncology wards, and intensive-care
units.
Prescribed antimicrobials were divided into four main categories using the WHO
AWaRe classification [14] and further grouped using the 2021 WHO ATC code classification
system [20]. AWaRe groups were Access, Watch, Reserve and Not Recommended. Those
that were not included in the classification were recorded as unclassified. Antimicrobials
were grouped into therapeutic subgroups (ATC 2 level) following the WHO ATC classifi-
cation system [20]. The therapeutic subgroups were antibacterials for systemic use (J01),
antimycotics and antifungals for systemic use (J02 and D01BA including griseofulvin and
terbinafine), drugs for treatment of tuberculosis (J04A), antibiotics used as intestinal anti-
infectives (A07AA), antiprotozoals used as antibacterial agents, nitroimidazole derivatives
(P01AB), antivirals for systemic use (J05) and antimalarials (P01B).
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Antimicrobial stewardship interventions as a result of PPS data: leads of all hospitals
were asked to provide a short summary of AMS interventions, detailing the actions taken
and any follow up data as a result of the PPS.
Data analysis: The results were analyzed descriptively and analytically using the R
software (version 4.1.0) and Microsoft Excel (2016). Antimicrobial use prevalence rates
were reported by calculating the number of patients on at least one antimicrobial relative
to the number of admitted patients at the time of the PPS using Microsoft Excel (2016). The
chi-squared test of association was conducted to compare national data on antimicrobial
use and identify associations between dependent and independent variables within the
dataset using the R software. The tests investigated the association between countries,
gender, age groups, and antibiotic prescription across the AWaRe categories. Age was split
into three categories namely: neonates (>1 month), children (1 month–17 years), and adults
(18 years and above). Statistical significance was set at p < 0.05.
Ethics: Formal ethics approval was not required at any hospital as there was no direct
patient contact and all data were anonymized. All sites obtained approval from their
respective hospital administration. Ethics review and approval was sought and obtained
in Uganda and administrative clearance by the participating hospitals was also given. For
the four additional sites in Ghana, formal ethical approval was received.
5. Conclusions
The prevalence of antimicrobial use in the hospitals included in this study was
50% (30–57%), with most antibiotics prescribed belonging to the WHO ‘Access’ and ‘Watch’
groups. No ‘Reserve’ category antibiotics were prescribed across the study sites. Not
Recommended antibiotics were prescribed, albeit infrequently. This aligns with previ-
ously published data in that the ‘Access’ and ‘Watch’ category antibiotics are commonly
prescribed in LMICs, although to varying extents across countries.
As a result of the CwPAMS health partnership programme and collaboration with
other hospitals, PPS data are available for the most part for the first time, strengthening
the global commitment to improved antimicrobial surveillance. AMS interventions as a
result of the PPSs conducted include formation of AMS committees, preparation of new
AMS guidelines and provision of training. Other common interventions included the
presentation of findings to clinicians, thus supporting awareness and the multi-disciplinary
approach to successful AMS programmes.
In order to continue to monitor the impact of interventions, repeat PPS should be
carried out and to strengthen the quality of data, widening participation is encouraged.
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.3390/antibiotics10091122/s1, Table S1: Most common reason for antimicrobial prescribing across 17
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